Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Jul 31:14:96.
doi: 10.1186/s12933-015-0261-9.

Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus

Affiliations
Review

Interplay between ultrastructural findings and atherothrombotic complications in type 2 diabetes mellitus

Prashilla Soma et al. Cardiovasc Diabetol. .

Abstract

Accelerated atherosclerosis is the main underlying factor contributing to the high risk of atherothrombotic events in patients with diabetes mellitus and atherothrombotic complications are the main cause of mortality. Like with many bodily systems, pathology is observed when the normal processes are exaggerated or uncontrolled. This applies to the processes of coagulation and thrombosis as well. In diabetes, in fact, the balance between prothrombotic and fibrinolytic factors is impaired and thus the scale is tipped towards a prothrombotic and hypofibrinolytic milieu, which in association with the vascular changes accompanying plaque formation and ruptures, increases the prevalence of ischaemic events such as angina and myocardial infarction. Apart from traditional, modifiable risk factors for cardiovascular disease like hypertension, smoking, elevated cholesterol; rheological properties, endogenous fibrinolysis and impaired platelet activity are rapidly gaining significance in the pathogenesis of atherosclerosis especially in diabetic subjects. Blood clot formation represents the last step in the athero-thrombotic process, and the structure of the fibrin network has a role in determining predisposition to cardiovascular disease. It is no surprise that just like platelets and fibrin networks, erythrocytes have been shown to play a role in coagulation as well. This is in striking contrast to their traditional physiological role of oxygen transport. In fact, emerging evidence suggests that erythrocytes enhance functional coagulation properties and platelet aggregation. Among the spectrum of haematological abnormalities in diabetes, erythrocyte aggregation and decreased deformability of erythrocytes predominate. More importantly, they are implicated in the pathogenesis of microvascular complications of diabetes. The morphology of platelets, fibrin networks and erythrocytes are thus essential role players in unravelling the pathogenesis of cardiovascular complications in diabetic subjects.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Outline of the review: cells involved in coagulation are described with characteristics thereof which contribute to atherosclerosis. Ultrastructural findings in all 3 cell types are then reviewed (TF tissue factor, FVII factor VII, t-PA tissue plasminogen activator, PAI-I plasminogen activator inhibitor I).
Fig. 2
Fig. 2
SEM of platelets, fibrin networks and erythrocytes. ac Taken from healthy individuals. df Taken from diabetic subjects. a Control platelet showing extended pseudopodia. b Major fibres and minor fibres of fibrin network, in a healthy control. c Erythrocyte of a healthy individual showing the typical morphology. d Diabetic platelets showing blebbed morphology. e Fibrin network of a diabetic subject showing dense matted deposits. f Diabetic erythrocyte entrapped in atypical fibrin fibres.

References

    1. van Rooy MJ, Pretorius E. Obesity, hypertension and hypercholesterolemia as risk factors for atherosclerosis leading to ischemic events. Curr Med Chem. 2014;21(19):2121–2129. doi: 10.2174/0929867321666131227162950. - DOI - PubMed
    1. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003;26(7):2181–2188. doi: 10.2337/diacare.26.7.2181. - DOI - PubMed
    1. Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation. 2003;108(12):1527–1532. doi: 10.1161/01.CIR.0000091257.27563.32. - DOI - PubMed
    1. Kluft C, Jespersen J. Review: diabetes as a procoagulant condition. Br J Diabetes Vasc Dis. 2002;2(5):358–362. doi: 10.1177/14746514020020050301. - DOI
    1. van Rooy MJ, Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thromb Res. 2015;135(3):434–442. doi: 10.1016/j.thromres.2014.12.030. - DOI - PubMed

Publication types

MeSH terms